It was reported that c‐MYC upregulates PD‐L1 expression on tumor cells.[38] Therefore, it is tempting to utilize more immunotherapy means such as immune checkpoint blockade antibodies (Anti‐PD‐L1, Anti‐CTLA‐4 antibodies) combining with I3A to improve immunotherapy efficacy. Here, MYC is linked to neoplasm.